Katsuhiko Hagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsuhiko Hagi has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Kohei Kaku
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
6 shared publications Kohjiro Ueki
Diabetes Research Center National Institute of Global Health and Medicine, Japan Institute for Health Security Tokyo Japan
6 shared publications- Hirotaka Watada
Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan
5 shared publications Kei Watabe
Data Science Sumitomo Pharma Co., Ltd. Tokyo Japan
5 shared publicationsKenji Kochi
Data Science, Sumitomo Pharma Co., Ltd. Tokyo Japan
4 shared publicationsTadafumi Kato
RIKEN, Ctr Brain Sci, Lab Mol Dynam Mental Disorders, Wako, Saitama, Japan
4 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 17 Ā (2) , 214-226
Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data
Introduction: Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement. Methods: Regression tree and random forest methods identified baseline characteristics predictive of HbA1c improvement. Partial dependence plots (PDP) visualized the relationship between HbA1c change and continuous variables deemed important by Boruta. Results: For monotherapy, key predictors were baseline HbA1c, hypertension, smoking, type 2 diabetes duration, body mass index (BMI), lowādensity lipoproteinācholesterol (LDLāC), metabolic syndrome, and estimated glomerular filtration rate. Nonsmokers with HbA1c ā„8.35% and LDLāC < 3.26 mmol/L at baseline showed the greatest improvement in HbA1c (ā1.24%). Random forest analysis and Boruta identified baseline HbA1c, BMI, fatty liver index, smoking, and hypertension as significant predictors of HbA1c improvement. PDPs identified a positive correlation between higher baseline HbA1c, and a negative correlation between BMI and fatty liver index, and HbA1c improvement. For imeglimin addāon to insulin therapy, key predictors were BMI, age, LDLāC, type 2 diabetes duration, systolic blood pressure, and alanine transaminase (ALT). Patients with BMI <25.9, LDLāC < 2.68 mmol/L, and ALT <21 U/L showed the greatest HbA1c improvement (ā1.48%). Random forest analysis and Boruta confirmed BMI, age, and LDLāC as significant predictors. PDPs identified a positive correlation between older age, and a negative correlation between higher BMI and LDLāC, and HbA1c improvement. Conclusions: Machine learning effectively identified baseline characteristics predictive of HbA1c response to imeglimin, supporting the potential for personalized type 2 diabetes treatment strategies.
- 8 December 2025
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 17 Ā (2) , 214-226
Open AccessPredictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data
Introduction: Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement. Methods: Regression tree and random forest methods identified baseline characteristics predictive of HbA1c improvement. Partial dependence plots (PDP) visualized the relationship between HbA1c change and continuous variables deemed important by Boruta. Results: For monotherapy, key predictors were baseline HbA1c, hypertension, smoking, type 2 diabetes duration, body mass index (BMI), lowādensity lipoproteinācholesterol (LDLāC), metabolic syndrome, and estimated glomerular filtration rate. Nonsmokers with HbA1c ā„8.35% and LDLāC < 3.26 mmol/L at baseline showed the greatest improvement in HbA1c (ā1.24%). Random forest analysis and Boruta identified baseline HbA1c, BMI, fatty liver index, smoking, and hypertension as significant predictors of HbA1c improvement. PDPs identified a positive correlation between higher baseline HbA1c, and a negative correlation between BMI and fatty liver index, and HbA1c improvement. For imeglimin addāon to insulin therapy, key predictors were BMI, age, LDLāC, type 2 diabetes duration, systolic blood pressure, and alanine transaminase (ALT). Patients with BMI <25.9, LDLāC < 2.68 mmol/L, and ALT <21 U/L showed the greatest HbA1c improvement (ā1.48%). Random forest analysis and Boruta confirmed BMI, age, and LDLāC as significant predictors. PDPs identified a positive correlation between older age, and a negative correlation between higher BMI and LDLāC, and HbA1c improvement. Conclusions: Machine learning effectively identified baseline characteristics predictive of HbA1c response to imeglimin, supporting the potential for personalized type 2 diabetes treatment strategies.
- Open Access
- 4 August 2025
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 16 Ā (10) , 1808-1819
Longāterm safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52āweek postmarketing clinical study ( TWINKLE )
Aim: To evaluate the longāterm safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD). Materials and Methods: This openālabel, singleāarm, multicenter, phase 4 study (TWINKLE) enrolled individuals with T2D and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m 2 , treated with ā¤1 oral hypoglycemic agent. Participants received 500 mg of imeglimin twice daily if eGFR was 15 to 2 or 500 mg once daily if eGFR was 2 , as monotherapy or in combination with their existing hypoglycemic agent, for 52 weeks. Dose adjustments were permitted based on safety and eGFR. Results: Among 60 participants (CKD stages: G3b: n = 42; G4: n = 16; G5: n = 2), adverse events (AEs) occurred in 41 participants (68.3%), with no increased incidence across CKD stages. The most common AE was diarrhea ( n = 6, 10.0%). Baseline mean (SD) HbA1c, glycated albumin (GA), and fasting plasma glucose (FPG) levels were 7.59% (0.68%), 22.53% (3.27%), and 151.8 (28.86) mg/dL, respectively. At week 24, mean (SD) changes from baseline were ā0.53% (0.51%) for HbA1c, ā2.37% (2.08%) for GA, and ā13.6 (20.87) mg/dL for FPG. At week 52 (last observation carried forward [LOCF]), mean changes were ā0.26% (0.88%), ā1.59% (3.04%), and ā7.0 (31.17) mg/dL. The proportion achieving HbA1c < 7.0% increased from 13.3% at baseline to 50.0% at week 52 (LOCF). Conclusions: This study confirmed the favorable safety profile and sustained glycemic efficacy of imeglimin in Japanese individuals with T2D and CKD stages G3bā5, supporting its use with dose adjustment in this population.
- 4 August 2025
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 16 Ā (10) , 1808-1819
Open AccessLongāterm safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52āweek postmarketing clinical study ( TWINKLE )
Aim: To evaluate the longāterm safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD). Materials and Methods: This openālabel, singleāarm, multicenter, phase 4 study (TWINKLE) enrolled individuals with T2D and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m 2 , treated with ā¤1 oral hypoglycemic agent. Participants received 500 mg of imeglimin twice daily if eGFR was 15 to 2 or 500 mg once daily if eGFR was 2 , as monotherapy or in combination with their existing hypoglycemic agent, for 52 weeks. Dose adjustments were permitted based on safety and eGFR. Results: Among 60 participants (CKD stages: G3b: n = 42; G4: n = 16; G5: n = 2), adverse events (AEs) occurred in 41 participants (68.3%), with no increased incidence across CKD stages. The most common AE was diarrhea ( n = 6, 10.0%). Baseline mean (SD) HbA1c, glycated albumin (GA), and fasting plasma glucose (FPG) levels were 7.59% (0.68%), 22.53% (3.27%), and 151.8 (28.86) mg/dL, respectively. At week 24, mean (SD) changes from baseline were ā0.53% (0.51%) for HbA1c, ā2.37% (2.08%) for GA, and ā13.6 (20.87) mg/dL for FPG. At week 52 (last observation carried forward [LOCF]), mean changes were ā0.26% (0.88%), ā1.59% (3.04%), and ā7.0 (31.17) mg/dL. The proportion achieving HbA1c < 7.0% increased from 13.3% at baseline to 50.0% at week 52 (LOCF). Conclusions: This study confirmed the favorable safety profile and sustained glycemic efficacy of imeglimin in Japanese individuals with T2D and CKD stages G3bā5, supporting its use with dose adjustment in this population.
- Open Access
- 26 December 2024
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 16 Ā (4) , 629-638
Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A postāhoc analysis of imeglimin clinical trial data
Introduction: An increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This postāhoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.Materials and Methods: Data were derived from the 52āweek, openālabel, phase 3 TIMESā2 trial in Japanese type 2 diabetes patients. Patients in the imeglimin plus metformin group were divided into two subgroups based on the presence of GI symptoms and diarrhea, with efficacy and safety assessed. Factors associated with their occurrence were explored using multivariate logistic regression analysis.Results: Of 64 patients analyzed, GI symptoms and diarrhea occurred in 40.6% (n = 26) and 17.2% (n = 11) of patients, respectively. Metformin dose and patient age did not significantly affect their incidence. Events occurred more frequently within the first 4 months of treatment. Approximately half resolved within 1 week, and most were mild. Type 2 diabetes duration P = 0.039). Significant hypoglycemic effects were observed from baseline, irrespective of GI symptoms or diarrhea. However, the degree of HbA1c improvement tended to be greater in patients with GI symptoms and diarrhea.Conclusions: Increased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.
- 26 December 2024
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 16 Ā (4) , 629-638
Open AccessGastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A postāhoc analysis of imeglimin clinical trial data
Introduction: An increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This postāhoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.Materials and Methods: Data were derived from the 52āweek, openālabel, phase 3 TIMESā2 trial in Japanese type 2 diabetes patients. Patients in the imeglimin plus metformin group were divided into two subgroups based on the presence of GI symptoms and diarrhea, with efficacy and safety assessed. Factors associated with their occurrence were explored using multivariate logistic regression analysis.Results: Of 64 patients analyzed, GI symptoms and diarrhea occurred in 40.6% (n = 26) and 17.2% (n = 11) of patients, respectively. Metformin dose and patient age did not significantly affect their incidence. Events occurred more frequently within the first 4 months of treatment. Approximately half resolved within 1 week, and most were mild. Type 2 diabetes duration P = 0.039). Significant hypoglycemic effects were observed from baseline, irrespective of GI symptoms or diarrhea. However, the degree of HbA1c improvement tended to be greater in patients with GI symptoms and diarrhea.Conclusions: Increased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.
- Open Access
- 25 June 2024
- Published byĀ WileyĀ inĀ Diabetes, Obesity and Metabolism
- Vol.Ā 26 Ā (9) , 3732-3742
Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by dataādriven cluster analysis: A postāhoc analysis of imeglimin clinical trial data
Aim: To explore differences in imeglimin response among type 2 diabetes (T2D) patient clusters using dataādriven cluster analysis. Methods: Dataādriven cluster analysis (nonāhierarchical kāmeans clustering) was performed on randomized, doubleāblind, imeglimin monotherapy and adjunctive (to insulin) therapy trials based on four baseline variables: (1) disease duration; (2) body mass index (BMI); (3) HbA1c; and (4a) homeostatic model assessment of βācell function (HOMAāβ) (monotherapy trials) or (4b) insulin total daily dose (adjunctive trial). Results: Four clusters were identified with distinct clinical characteristics in both monotherapy (1ā4) and adjunctive therapy (IāIV) trials; clusters 1 and I had lower values across all four indices versus the overall population, clusters 2 and II had a longer diabetes duration, cluster 3 had higher baseline BMI and HOMAāβ, and cluster III had higher baseline BMI and insulin total daily dose, while clusters 4 and IV had higher baseline HbA1c. Betweenāgroup differences in HbA1c change (95% confidence interval) and effect size (ES) at week 24 varied considerably by cluster (cluster 1: ā0.82 [ā1.00, ā0.63], ES = 1.47; cluster 2: ā0.64 [ā0.89, ā0.39], ES = 1.18; cluster 3: ā0.86 [ā1.38, ā0.33], ES = 0.84; cluster 4: ā1.27 [ā1.73, ā0.82], ES = 1.44). For imeglimin adjunctive therapy, HbA1c improvements were significant versus placebo at week 16, excluding cluster III (cluster I: ā0.63 [ā0.95, ā0.31], ES = 0.88; cluster II: ā0.66 [ā1.02, ā0.30], ES = 1.13; cluster III: ā0.31 [ā0.73, 0.11], ES = 0.46; cluster IV: ā0.82 [ā1.29, ā0.35], ES = 0.99). Conclusions: Differences in imeglimin response were observed among T2D patient clusters. Patient stratification may help with selection of those most probable to respond to imeglimin.
- 25 June 2024
- Published byĀ WileyĀ inĀ Diabetes, Obesity and Metabolism
- Vol.Ā 26 Ā (9) , 3732-3742
Open AccessDifferences in imeglimin response in subgroups of patients with type 2 diabetes stratified by dataādriven cluster analysis: A postāhoc analysis of imeglimin clinical trial data
Aim: To explore differences in imeglimin response among type 2 diabetes (T2D) patient clusters using dataādriven cluster analysis. Methods: Dataādriven cluster analysis (nonāhierarchical kāmeans clustering) was performed on randomized, doubleāblind, imeglimin monotherapy and adjunctive (to insulin) therapy trials based on four baseline variables: (1) disease duration; (2) body mass index (BMI); (3) HbA1c; and (4a) homeostatic model assessment of βācell function (HOMAāβ) (monotherapy trials) or (4b) insulin total daily dose (adjunctive trial). Results: Four clusters were identified with distinct clinical characteristics in both monotherapy (1ā4) and adjunctive therapy (IāIV) trials; clusters 1 and I had lower values across all four indices versus the overall population, clusters 2 and II had a longer diabetes duration, cluster 3 had higher baseline BMI and HOMAāβ, and cluster III had higher baseline BMI and insulin total daily dose, while clusters 4 and IV had higher baseline HbA1c. Betweenāgroup differences in HbA1c change (95% confidence interval) and effect size (ES) at week 24 varied considerably by cluster (cluster 1: ā0.82 [ā1.00, ā0.63], ES = 1.47; cluster 2: ā0.64 [ā0.89, ā0.39], ES = 1.18; cluster 3: ā0.86 [ā1.38, ā0.33], ES = 0.84; cluster 4: ā1.27 [ā1.73, ā0.82], ES = 1.44). For imeglimin adjunctive therapy, HbA1c improvements were significant versus placebo at week 16, excluding cluster III (cluster I: ā0.63 [ā0.95, ā0.31], ES = 0.88; cluster II: ā0.66 [ā1.02, ā0.30], ES = 1.13; cluster III: ā0.31 [ā0.73, 0.11], ES = 0.46; cluster IV: ā0.82 [ā1.29, ā0.35], ES = 0.99). Conclusions: Differences in imeglimin response were observed among T2D patient clusters. Patient stratification may help with selection of those most probable to respond to imeglimin.
- Open Access
- 25 May 2024
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 15 Ā (9) , 1239-1247
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus
Aims/Introduction: To investigate the effect of patient characteristics on imeglimin effectiveness in Japanese patients with type 2 diabetes mellitus.Materials and Methods: Data were pooled from two randomized, placeboācontrolled, 24āweek, doubleāblind studies of imeglimin monotherapy in Japanese adults with type 2 diabetes mellitus, with the proportion of responders (glycated hemoglobin [HbA1c] < 7.0%) and sustained responders (i.e., achieved and maintained response) in the imeglimin 1,000 mg twice daily group calculated at each visit. Patient factors significantly (P < 0.05) correlated with response were explored through multivariate logistic regression. Subgroup analyses compared the efficacy of imeglimin in patients with a HbA1c improvement less than or equal to ā0.3% (early responders) versus greater than ā0.3% (early nonāresponders) at week 4.Results: A total of 38.0% of imegliminātreated patients and 7.2% of placeboātreated patients were responders (P < 0.001, number needed to treat = 4). The proportion of sustained responders at weeks 4, 8, 12, 16 and 20 was 10.6, 19.0, 24.0, 25.7 and 29.1%, respectively (>70% of responders at each visit). Improvements in HbA1c and fasting glucose were significantly greater in early responders versus early nonāresponders from week 4; betweenāgroup differences remained significant to week 24. Older age (odds ratio 1.09, 95% confidence interval 1.04ā1.14; P < 0.001); treatmentānaĆÆve status vs previous treatment (odds ratio 3.70, 95% confidence interval 1.55ā8.82; P = 0.003), and lower baseline HbA1c (odds ratio 0.06, 95% confidence interval 0.02ā0.16; P < 0.001) predicted response.Conclusions: A significantly higher proportion of patients receiving imeglimin 1,000 mg twice daily monotherapy were responders versus placebo. Most (>70%) were sustained responders, suggesting that response is fairly predictable. Older age, treatmentānaĆÆve status and early treatment response significantly predicted imeglimin effectiveness.
- 25 May 2024
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 15 Ā (9) , 1239-1247
Open AccessFactors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus
Aims/Introduction: To investigate the effect of patient characteristics on imeglimin effectiveness in Japanese patients with type 2 diabetes mellitus.Materials and Methods: Data were pooled from two randomized, placeboācontrolled, 24āweek, doubleāblind studies of imeglimin monotherapy in Japanese adults with type 2 diabetes mellitus, with the proportion of responders (glycated hemoglobin [HbA1c] < 7.0%) and sustained responders (i.e., achieved and maintained response) in the imeglimin 1,000 mg twice daily group calculated at each visit. Patient factors significantly (P < 0.05) correlated with response were explored through multivariate logistic regression. Subgroup analyses compared the efficacy of imeglimin in patients with a HbA1c improvement less than or equal to ā0.3% (early responders) versus greater than ā0.3% (early nonāresponders) at week 4.Results: A total of 38.0% of imegliminātreated patients and 7.2% of placeboātreated patients were responders (P < 0.001, number needed to treat = 4). The proportion of sustained responders at weeks 4, 8, 12, 16 and 20 was 10.6, 19.0, 24.0, 25.7 and 29.1%, respectively (>70% of responders at each visit). Improvements in HbA1c and fasting glucose were significantly greater in early responders versus early nonāresponders from week 4; betweenāgroup differences remained significant to week 24. Older age (odds ratio 1.09, 95% confidence interval 1.04ā1.14; P < 0.001); treatmentānaĆÆve status vs previous treatment (odds ratio 3.70, 95% confidence interval 1.55ā8.82; P = 0.003), and lower baseline HbA1c (odds ratio 0.06, 95% confidence interval 0.02ā0.16; P < 0.001) predicted response.Conclusions: A significantly higher proportion of patients receiving imeglimin 1,000 mg twice daily monotherapy were responders versus placebo. Most (>70%) were sustained responders, suggesting that response is fairly predictable. Older age, treatmentānaĆÆve status and early treatment response significantly predicted imeglimin effectiveness.
- Top Cited PapersOpen Access
- 1 September 2023
- Published byĀ Royal College of PsychiatristsĀ inĀ The British Journal of Psychiatry
- Vol.Ā 223 Ā (3) , 407-414
Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials
Background: The COVID-19 pandemic has transformed healthcare significantly and telepsychiatry is now the primary means of treatment in some countries.Aims: To compare the efficacy of telepsychiatry and face-to-face treatment.Method: A comprehensive meta-analysis comparing telepsychiatry with face-to-face treatment for psychiatric disorders. The primary outcome was the mean change in the standard symptom scale scores used for each psychiatric disorder. Secondary outcomes included all meta-analysable outcomes, such as all-cause discontinuation and safety/tolerability.Results: We identified 32 studies (n = 3592 participants) across 11 mental illnesses. Disease-specific analyses showed that telepsychiatry was superior to face-to-face treatment regarding symptom improvement for depressive disorders (k = 6 studies, n = 561; standardised mean difference s.m.d. = ā0.325, 95% CI ā0.640 to ā0.011, P = 0.043), whereas face-to-face treatment was superior to telepsychiatry for eating disorder (k = 1, n = 128; s.m.d. = 0.368, 95% CI 0.018ā0.717, P = 0.039). No significant difference was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 26, n = 2290; P = 0.248). Telepsychiatry had significantly fewer all-cause discontinuations than face-to-face treatment for mild cognitive impairment (k = 1, n = 61; risk ratio RR = 0.552, 95% CI 0.312ā0.975, P = 0.040), whereas the opposite was seen for substance misuse (k = 1, n = 85; RR = 37.41, 95% CI 2.356ā594.1, P = 0.010). No significant difference regarding all-cause discontinuation was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 27, n = 3341; P = 0.564).Conclusions: Telepsychiatry achieved a symptom improvement effect for various psychiatric disorders similar to that of face-to-face treatment. However, some superiorities/inferiorities were seen across a few specific psychiatric disorders, suggesting that its efficacy may vary according to disease type.
- 1 September 2023
- Published byĀ Royal College of PsychiatristsĀ inĀ The British Journal of Psychiatry
- Vol.Ā 223 Ā (3) , 407-414
Top Cited PapersOpen AccessTelepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials
Background: The COVID-19 pandemic has transformed healthcare significantly and telepsychiatry is now the primary means of treatment in some countries.Aims: To compare the efficacy of telepsychiatry and face-to-face treatment.Method: A comprehensive meta-analysis comparing telepsychiatry with face-to-face treatment for psychiatric disorders. The primary outcome was the mean change in the standard symptom scale scores used for each psychiatric disorder. Secondary outcomes included all meta-analysable outcomes, such as all-cause discontinuation and safety/tolerability.Results: We identified 32 studies (n = 3592 participants) across 11 mental illnesses. Disease-specific analyses showed that telepsychiatry was superior to face-to-face treatment regarding symptom improvement for depressive disorders (k = 6 studies, n = 561; standardised mean difference s.m.d. = ā0.325, 95% CI ā0.640 to ā0.011, P = 0.043), whereas face-to-face treatment was superior to telepsychiatry for eating disorder (k = 1, n = 128; s.m.d. = 0.368, 95% CI 0.018ā0.717, P = 0.039). No significant difference was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 26, n = 2290; P = 0.248). Telepsychiatry had significantly fewer all-cause discontinuations than face-to-face treatment for mild cognitive impairment (k = 1, n = 61; risk ratio RR = 0.552, 95% CI 0.312ā0.975, P = 0.040), whereas the opposite was seen for substance misuse (k = 1, n = 85; RR = 37.41, 95% CI 2.356ā594.1, P = 0.010). No significant difference regarding all-cause discontinuation was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 27, n = 3341; P = 0.564).Conclusions: Telepsychiatry achieved a symptom improvement effect for various psychiatric disorders similar to that of face-to-face treatment. However, some superiorities/inferiorities were seen across a few specific psychiatric disorders, suggesting that its efficacy may vary according to disease type.
- Open Access
- 23 August 2023
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 14 Ā (11) , 1246-1261
Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A metaāanalysis of randomized controlled trials
Aims/Introduction: This metaāanalysis aimed to evaluate the efficacy and safety/tolerability of imeglimin, a novel oral antihyperglycemic agent, administered as monotherapy and adjunctive therapy in patients with type 2 diabetes mellitus.Materials and Methods: Parallelāgroup randomized controlled trials comparing imeglimin with placebo in adults with type 2 diabetes mellitus were included. Risk ratios or weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated using random effects models. The primary outcome for efficacy was the change in glycated hemoglobin (HbA1c). Secondary outcomes included other efficacyārelated outcomes, specific adverse events, and changes in body weight and lipid parameters.Results: Nine randomized controlled trials (n = 1,655) were included. When analyzed by dose, there was a significant difference in glycated hemoglobin (%) between imeglimin monotherapy and placebo at doses >1,000 mg twice daily (1,000 mg: studies N = 3, patients n = 517, WMD = ā0.714, P < 0.001; 1,500 mg: N = 5, n = 448, WMD = ā0.531, P = 0.020; 2,000 mg: N = 1, n = 149, WMD = ā0.450, P = 0.005). Imeglimin adjunctive therapy significantly improved glycated hemoglobin over placebo at doses of 1,000 mg (N = 1, n = 214, WMD = ā0.600, P < 0.001) and 1,500 mg (N = 2, n = 324, WMD = ā0.576, P < 0.001). Subgroup analysis of the primary outcome showed that imeglimin was effective regardless of chronic kidney disease category, with studies carried out in Japan and in patients with lower body mass index showing a trend toward improved imeglimin efficacy. There were no significant differences between imeglimin and placebo in the risk of allācause discontinuation and the proportion of patients who presented with at least one adverse event.Conclusions: Imeglimin is efficacious, safe, and well tolerated as monotherapy and adjunctive therapy.
- 23 August 2023
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 14 Ā (11) , 1246-1261
Open AccessEfficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A metaāanalysis of randomized controlled trials
Aims/Introduction: This metaāanalysis aimed to evaluate the efficacy and safety/tolerability of imeglimin, a novel oral antihyperglycemic agent, administered as monotherapy and adjunctive therapy in patients with type 2 diabetes mellitus.Materials and Methods: Parallelāgroup randomized controlled trials comparing imeglimin with placebo in adults with type 2 diabetes mellitus were included. Risk ratios or weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated using random effects models. The primary outcome for efficacy was the change in glycated hemoglobin (HbA1c). Secondary outcomes included other efficacyārelated outcomes, specific adverse events, and changes in body weight and lipid parameters.Results: Nine randomized controlled trials (n = 1,655) were included. When analyzed by dose, there was a significant difference in glycated hemoglobin (%) between imeglimin monotherapy and placebo at doses >1,000 mg twice daily (1,000 mg: studies N = 3, patients n = 517, WMD = ā0.714, P < 0.001; 1,500 mg: N = 5, n = 448, WMD = ā0.531, P = 0.020; 2,000 mg: N = 1, n = 149, WMD = ā0.450, P = 0.005). Imeglimin adjunctive therapy significantly improved glycated hemoglobin over placebo at doses of 1,000 mg (N = 1, n = 214, WMD = ā0.600, P < 0.001) and 1,500 mg (N = 2, n = 324, WMD = ā0.576, P < 0.001). Subgroup analysis of the primary outcome showed that imeglimin was effective regardless of chronic kidney disease category, with studies carried out in Japan and in patients with lower body mass index showing a trend toward improved imeglimin efficacy. There were no significant differences between imeglimin and placebo in the risk of allācause discontinuation and the proportion of patients who presented with at least one adverse event.Conclusions: Imeglimin is efficacious, safe, and well tolerated as monotherapy and adjunctive therapy.
- Open Access
- 1 June 2023
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 14 Ā (9) , 1101-1109
Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A postāhoc analysis of two randomized, placeboācontrolled trials
Aims/Introduction: Substantial variability in demographic and clinical characteristics exists among patients with type 2 diabetes mellitus, which may impact treatment. This postāhoc analysis evaluated the efficacy and safety of imeglimin 1,000 mg twice daily (BID) monotherapy in type 2 diabetes mellitus patients according to demographic and clinical characteristics.Materials and Methods: Data were pooled from two placeboācontrolled, 24 week, randomized, doubleāblind studies in adults with type 2 diabetes mellitus. Outcomes (least squares mean [LSM] change in HbA1c from baseline to week 24, and safety) were analyzed according to subgroups based on demographics, clinical characteristics, and comorbidities.Results: The difference in LSM change in HbA1c from baseline to week 24 was statistically significant for imeglimin vs placebo in all patient subgroups analyzed (P < 0.05 each), including demographics (age, body mass index), clinical characteristics (duration of type 2 diabetes mellitus, chronic kidney disease [CKD] stage, and prior medication use) and comorbidities (hypertension, dyslipidemia, risk of hepatic fibrosis and liver function parameter status). A statistically significant separation from placebo in HbA1c was observed at week 4 and maintained through week 24. No new safety concerns were identified with imeglimin in any patient subpopulations.Conclusions: The efficacy and safety of imeglimin was demonstrated across patient subgroups, irrespective of baseline demographic and clinical characteristics. Our findings confirm the efficacy and safety of imeglimin across a broad spectrum of patients with type 2 diabetes mellitus.
- 1 June 2023
- Published byĀ WileyĀ inĀ Journal of Diabetes Investigation
- Vol.Ā 14 Ā (9) , 1101-1109
Open AccessEffect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A postāhoc analysis of two randomized, placeboācontrolled trials
Aims/Introduction: Substantial variability in demographic and clinical characteristics exists among patients with type 2 diabetes mellitus, which may impact treatment. This postāhoc analysis evaluated the efficacy and safety of imeglimin 1,000 mg twice daily (BID) monotherapy in type 2 diabetes mellitus patients according to demographic and clinical characteristics.Materials and Methods: Data were pooled from two placeboācontrolled, 24 week, randomized, doubleāblind studies in adults with type 2 diabetes mellitus. Outcomes (least squares mean [LSM] change in HbA1c from baseline to week 24, and safety) were analyzed according to subgroups based on demographics, clinical characteristics, and comorbidities.Results: The difference in LSM change in HbA1c from baseline to week 24 was statistically significant for imeglimin vs placebo in all patient subgroups analyzed (P < 0.05 each), including demographics (age, body mass index), clinical characteristics (duration of type 2 diabetes mellitus, chronic kidney disease [CKD] stage, and prior medication use) and comorbidities (hypertension, dyslipidemia, risk of hepatic fibrosis and liver function parameter status). A statistically significant separation from placebo in HbA1c was observed at week 4 and maintained through week 24. No new safety concerns were identified with imeglimin in any patient subpopulations.Conclusions: The efficacy and safety of imeglimin was demonstrated across patient subgroups, irrespective of baseline demographic and clinical characteristics. Our findings confirm the efficacy and safety of imeglimin across a broad spectrum of patients with type 2 diabetes mellitus.
- 1 February 2022
- Published byĀ ElsevierĀ inĀ Journal of the American Academy of Child & Adolescent Psychiatry
- Vol.Ā 61 Ā (2) , 243-254
Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression
- 1 February 2022
- Published byĀ ElsevierĀ inĀ Journal of the American Academy of Child & Adolescent Psychiatry
- Vol.Ā 61 Ā (2) , 243-254
Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression